Depot antipsychotic use in schizophrenia: An East Asian perspective

Human Psychopharmacology

Volumn 19, Issue 2, 2004, Pages 103-109

  Sim, Kang ^a   Su, Alex ^a   Ungvari, Gabor S ^b   Fujii, Senta ^c   Yang, Shu Yu ^d   Chong, Mian Yoon ^d   Si, Tianmei ^e   Chung, Eun Kee ^f   Tsang, Hin Yeung ^d   Chan, Yiong Huak ^g   Shinfuku, Naotaka ^c   Tan, Chay Hoon ^h  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c KOBE UNIVERSITY   (Japan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e PEKING UNIVERSITY   (China)

^f Seoul National University Hospital   (South Korea)

^g MINISTRY OF HEALTH   (Singapore)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticholinergic; Antipsychotic; Atypical; Depot; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL DECANOATE; PIPOTIAZINE PALMITATE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGE; AGGRESSION; AKATHISIA; ARTICLE; ASIA; CHINA; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DELUSION; DISEASE DURATION; DOSE RESPONSE; DYSTONIA; FEMALE; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MENTAL PATIENT; MULTIVARIATE ANALYSIS; PARKINSONISM; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEX DETERMINATION; SINGAPORE; SPEECH DISORDER; STANDARDIZATION; SYMPTOMATOLOGY; TAIWAN; TARDIVE DYSKINESIA; XEROSTOMIA;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DELAYED-ACTION PREPARATIONS; FAR EAST; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 12144289974     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.571     Document Type: Article

References (39)

1. Adams CE, Fenton MK, Quraishi S, David AS. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179: 290-299.
2. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo, E. 2003. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63: 493-512.
3. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4 edn. American Psychiatric Press: Washington, DC.
4. American Psychiatric Association. 1997. Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric Press: Washington, DC.
5. Barnes TR, Curson DA. 1994. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 10: 464-479.
6. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. 2001. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 62: 855-859.
7. Bosveld-van Haandel LJ, Slooff CJ, van den Bosch RJ. 2001. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 103: 335-346.
8. Castle D, Morgan V, Jablensky A. 2002. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 36: 633-641.
9. Citrome L, Levine J, Allingham B. 1996. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 32: 321-326.
10. Coutinho E, Fenton M, Quraishi S. 2000. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev (2): CD001164.
11. Covell NH, Jackson CT, Evans AC, Essock SM. 2002. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28: 17-29.
12. Davis JM, Matalon L, Watanabe MD, Blake L. 1994. Depot antipsychotic drugs: place in therapy. Drugs 47: 741-773.
13. Gerlach J. 1995. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9(Suppl 5): 17-20.
14. Glazer WM, Kane JM. 1992. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 53: 426-433.
15. Gruber AJ, Cole JO. 1991. Antidepressant effects of flupenthixol. Pharmacotherapy 11: 450-459.
16. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB, SOHO Study Group. 2003. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand Suppl 416: 7-15.
17. Heyscue BE, Levin GM, Merrick JP. 1998. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 49: 1232-1234.
18. Hogarty GE. 1984. Depot neuroleptics: the relevance of psychosocial factors - a United States perspective. J Clin Psychiatry 45: 36-42.
19. Inagaki A, Inada T, Fujii Y, Yagi G. 1999. Equivalent Doses of Psychotropics. Seiwa Shoten: Tokyo.
20. Kane JM. 1996. Schizophrenia. N Engl J Med 334: 34-41.
21. Kane JM, Aguglia E, Altamura AC, et al. 1998. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66.
22. Keks NA, Altson K, Hope J, et al. 1999. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33: 896-901.
23. Knapp M, Ilson S, David A. 2002. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence. Int Clin Psychopharmacol 17: 135-140.
24. Lambert TJ, Castle DJ. 2003. Pharmacological approaches to the management of schizophrenia. Med J Aust 178(Suppl): S57-S61.
25. Larsen EB, Gerlach J. 1996. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 93: 381-388.
26. Lee S. 1995. Polypharmacy. Aust N Z J Psychiatry 29: 690-691.
27. Marder SR. 1986. Depot neuroleptics: side effects and safety. J Clin Psychopharmacol 6(1 Suppl): 24S-29S.
28. Marland GR, Sharkey V. 1999. Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. J Adv Nurs 30: 1255-1262.
29. Milton GV, Jann MW. 1995. Emergency treatment of psychotic symptoms: pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet 28: 494-504.
30. Muir-Cochrane EC. 1998. The role of the community mental health nurse in the administration of depot neuroleptic medication: 'not just the needle nurse!'. Int J Nurs Pract 4: 254-260.
31. Patel MX, Nikolaou V, David AS. 2003. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33: 83-89.
32. Quraishi S, David A. 2001. Depot pipothiazine palmitate and undecylenate for schizophrenia. Cochrane Database Syst Rev (3): CD001720.
33. Simpson GM. 1984. A brief history of depot neuroleptics. J Clin Psychiatry 45: 3-4.
34. Tavcar R, Dernovsek MZ, Zvan V. 2000. Choosing antipsychotic maintenance therapy - a naturalistic study. Pharmacopsychiatry 33: 66-71.
35. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. 2001. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 62: 545-551.
36. Walburn J, Gray R, Gournay K, Quraishi S, David AS. 2001. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300-307.
37. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. 2000. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 61: 344-348.
38. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. 1995. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 46: 1049-1054.
39. World Health Organization. 1992. International Statistical Classification of Diseases and Related Health Problems, 10th revision. World Health Organization: Geneva.